- Home
- CGEM vs AHG Comparison
CGEM vs AHG Comparison
Compare CGEM & AHG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGEM | AHG |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CGEM | AHG |
|---|---|---|
| Price | $19.60 | $1.47 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $30.13 | N/A |
| AVG Volume (30 Days) | ★ 524.7K | 6.8K |
| Earning Date | 05-11-2026 | 08-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.20 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.68 | $1.10 |
| 52 Week High | $19.82 | $2.50 |
Technical Indicators
Market Signals| Indicator | CGEM | AHG |
|---|---|---|
| Relative Strength Index (RSI) | 66.45 | 43.82 |
| Support Level | $11.87 | $1.24 |
| Resistance Level | N/A | $1.64 |
| Average True Range (ATR) | 0.99 | 0.11 |
| MACD | 0.20 | -0.01 |
| Stochastic Oscillator | 93.11 | 37.15 |
Price Performance
Historical ComparisonAbout CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
About AHG Akso Health Group ADS
Akso Health Group is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.